Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
《药物经济学和结果研究专家评论》 （ISSN 1473 - 7167 ）提供了与药物临床使用和治疗方法相关的成本效益和药物经济学问题的专家评论。覆盖范围包括药物经济学和生活质量研究、治疗结果、循证医学和成本效益研究。所有文章均经过严格的同行评审。该杂志采用独特的专家评审文章格式，提供了一个关键技术领域、研究或临床实践的当前思想的完整概述，并通过以下章节进行了补充：专家意见-对文章中数据的个人观点，对未来可能重要的发展的讨论，以及随着进一步研究产生更详细的结果而可能变得令人兴奋的研究途径文章要点-作者最关键观点的执行摘要。
Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1575730
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2018.1518134
Cognitive behavior therapy for health anxiety: systematic review and meta-analysis of clinical efficacy and health economic outcomes
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1703182
The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2020.1678385
Cost burden of diffuse large B-cell lymphoma
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1680288
Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2017.1347041
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1647104
Review of studies reporting actual prices for medicines
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1552137
Cross-national drug price comparisons with economic weights in external reference pricing in Germany
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1527221
The evolving role of patient advocates in rare cancers: opportunities and challenges
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1526083
How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1702524
Reviewing estimates of the burden in disability-adjusted life years (DALYs) of tick-borne encephalitis in Slovenia
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1573677
Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1554437
Analysis of prevalence, risk factors, and potential costs of unnecessary drug therapy in patients with chronic diseases at the outpatient setting
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1612243
Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1667232
Effects of economic and health policies on the consumption of antibiotics in a Spanish region
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1647105
Review of health economic analyses in atopic dermatitis: how diverse is the literature?
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1549491
Direct cost of Parkinson’s disease in a health system with high judicialization: evidence from Colombia
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2020.1681266
Disease activity and sleep quality in rheumatoid arthritis: a deeper look into the relationship
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2020.1677156
Adding two culture-specific ‘bolt-on’ dimensions on the Thai version of EQ-5D-5L: an exploratory study in patients with diabetes
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1525294
Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2018.1518135
Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1541404
Evaluation of Jordanian Healthcare Providers’ Knowledge, Attitudes, and Practice Patterns towards Probiotics
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1609354
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1527220
Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1626720
Quality of life and costs of patients prior to colorectal surgery
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1628641
Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1592680
Measuring quality of life in COPD patients: comparing disease-specific supplements to the EQ-5D-5L
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1662302
Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1629291
Breast Cancer Quality of Life and Health-state Utility at a Brazilian Reference Public Cancer Center
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1621752
Achieving cost-efficient management of drug supply via economic order quantity and minimum-maximum stock level
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1633308
Value-based medicine and palliative care: how do they converge?
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1651645
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1635014
Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1629905
A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1644169
Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1615886
The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2020.1688146
Systematic literature review on the economic, humanistic, and societal burden of heart failure in children and adolescents
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1579645
Pharmaceutical expenditure and total health-care expenditure in OECD countries and China: bidirectional Granger causality on the basis of health level.
来源期刊：Expert review of pharmacoeconomics & outcomes researchDOI：10.1080/14737167.2019.1605292
Economic evaluations of oral medications for breast cancer treatment in the U.S.: a systematic review with a focus on cost-effectiveness threshold
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1680289
Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1702879
The direct and indirect costs of epilepsy in Poland estimates for 2014–2016 years
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1533817
Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1702525
Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1702523
A systematic review and cost analysis of repeat colonoscopies due to inadequate bowel cleansing in five European countries
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1597709
The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1650024
Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1580572
Evaluating intensive care unit medication charges in a teaching hospital in Jordan
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1571413
Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2019.1582334
Intrinsic properties of medical devices: considerations for economic evaluation
来源期刊：Expert Review of Pharmacoeconomics & Outcomes ResearchDOI：10.1080/14737167.2020.1693268
